Clinical Trial Update: A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL) [Phase 3]

View source ↗

Summary

Phase III randomized, double-blind, placebo-controlled multicenter trial evaluating panobinostat as maintenance therapy in Hodgkin lymphoma has completed, with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Panobinostat (Panobinostat)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hodgkin's Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2016-07-07